Capstone Therapeutics Corp. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2011. The filing identifies the registrant as Capstone Therapeutics Corp., formerly OrthoLogic Corp.; this differs from the requested company name, Capstone Holding Corp. The company was a development-stage biotechnology company focused on AZX100 and Chrysalin (TP508).
Business Context and Financial Position
- AZX100 was being evaluated for dermal scarring and pulmonary disease applications. Phase 2 studies for keloid scar revision were completed in 2010, and the shoulder-surgery dermal-scarring study was substantially completed in 2010; results were reported in April 2011.
- Chrysalin development was focused on partnering or licensing opportunities, with no additional clinical studies then planned.
- Common shares outstanding were 40.8 million as of July 31, 2011.
- The company operated as a single reportable segment and had accumulated approximately $142.1 million of development-stage net losses through June 30, 2011.
Key Financial Metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Operating expenses | $2.173 million in 2011; $2.949 million in 2010 | $5.420 million in 2011; $5.945 million in 2010 |
| Research and development expense | $1.376 million; $2.160 million prior year | $3.458 million; $4.183 million prior year |
| General and administrative expense | $797,000; $789,000 prior year | $1.962 million; $1.762 million prior year |
| Net loss | $2.169 million, or $0.05 per share; $2.923 million, or $0.07 prior year | $5.406 million, or $0.13 per share; $5.874 million, or $0.14 prior year |
| Cash flow from operations | Not separately reported for the quarter | $(4.760) million; $(5.100) million prior year |
Liquidity: Cash and cash equivalents were $19.608 million at June 30, 2011, compared with $24.387 million at December 31, 2010. Total assets were $19.992 million and current liabilities were $1.162 million. The filing reports no debt. Management stated that existing cash was expected to satisfy presently projected cash and working-capital requirements for the next year, but additional capital would be required to complete clinical development and supporting work necessary for FDA approval.
Margins: Not meaningful because the company reported no revenue and remained in the development stage.
Material Changes Versus Prior Comparable Period
- Second-quarter operating expenses declined $776,000, primarily because Phase 2 clinical costs decreased after completion or substantial completion of key studies.
- Six-month operating expenses declined $525,000. Lower clinical costs were partly offset by higher internal research, AZX100 peptide acquisition, investor-relations, and business-development costs.
- Net loss improved by $754,000 in the second quarter and by $468,000 for the six-month period.
- Interest and other income declined to $4,000 for the quarter and $14,000 for six months, from $26,000 and $71,000, respectively, because less cash was available for investment and investments were shifted to maturities of 90 days or less.
- Cash declined $4.779 million during the first six months, primarily reflecting operating cash use of $4.760 million.
- Share-based payment liabilities were reduced to zero; $375,000 was recognized as a reduction during the quarter and $660,000 during the six-month period, with corresponding increases to additional paid-in capital.
Outlook, Risks, Contingencies, and Unusual Items
- Management intended to continue preclinical and research activities for AZX100 while pursuing development collaborations, licensing, or partnering opportunities for AZX100 and Chrysalin.
- Future research and development spending could vary significantly depending on development decisions. The filing does not provide quantitative earnings or revenue guidance.
- Put rights granted to stockholders were deemed to have expired on June 30, 2011. The board concluded that, because of the potential impact of the pending litigation, the company could not purchase shares under the put-right provisions.
- A qui tam lawsuit relating to the former bone-growth-stimulation business was proceeding toward discovery and trial. The relator seeks civil penalties and potentially treble damages that could exceed the company’s financial resources. Management believed an unfavorable outcome was not probable, but acknowledged that the outcome was uncertain and could materially impair liquidity, financial condition, operations, and continuity of the business.
- The company’s common stock was delisted from the Nasdaq Capital Market effective July 21, 2011 and subsequently traded on the OTC Bulletin Board and OTC Link System. The filing warns of reduced liquidity, penny-stock restrictions, lower trading prices, and potentially reduced access to capital.
- Management stated that the prior going-concern uncertainty related to the put rights no longer raised substantial doubt as of June 30, 2011. This conclusion depended on the expiration of the put rights and does not eliminate the risks associated with ongoing cash burn, litigation, or future financing needs.
- Management reported that disclosure controls and procedures were effective and that no material changes occurred in internal control over financial reporting during the quarter.
Investor Verification Points
- Verify the registrant identity and ticker because the filing is for Capstone Therapeutics Corp., not Capstone Holding Corp.
- Confirm the post-period Nasdaq delisting, current OTC quotation status, trading liquidity, and access to future capital.
- Review the status, potential damages, insurance or indemnification coverage, and liquidity implications of the qui tam litigation.
- Assess whether $19.6 million of cash is sufficient for the company’s planned research, corporate expenses, and litigation-related requirements.
- Determine whether AZX100 or Chrysalin has obtained a development or licensing partner and whether additional clinical trials are planned.
- Reconcile the filing’s reported second-quarter net loss of $2.169 million with management’s rounded reference to approximately $2.2 million.